The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
Open accessAbstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide. Many individuals have risk factors associated with NAFLD, but the majority do not develop advanced liver disease: cirrhosis, hepatic decompensation, or hepatocellular carcinoma. Identifying people at high risk of experiencing these complications is important in order to prevent disease progression. This review synthesises the evidence on metabolic risk factors and their potential to predict liver disease outcomes in the general population at risk of NAFLD or with diagnosed NAFLD. METHODS AND FINDINGS: We conducted a systematic review and meta-analysis of population-based cohort studies. Databases (including MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov) were searched up to 9 January 2020. Studies were included that reported severe liver disease outcomes (defined as liver cirrhosis, complications of cirrhosis, or liver-related death) or advanced fibrosis/non-alcoholic steatohepatitis (NASH) in adult individuals with metabolic risk factors, compared with individuals with no metabolic risk factors. Cohorts selected on the basis of a clinically indicated liver biopsy were excluded to better reflect general population risk. Risk of bias was assessed using the QUIPS tool. The results of similar studies were pooled, and overall estimates of hazard ratio (HR) were obtained using random-effects meta-analyses. Of 7,300 unique citations, 22 studies met the inclusion criteria and were of sufficient quality, with 18 studies contributing data suitable for pooling in 2 random-effects meta-analyses. Type 2 diabetes mellitus (T2DM) was associated with an increased risk of incident severe liver disease events (adjusted HR 2.25, 95% CI 1.83-2.76, p < 0.001, I2 99%). T2DM data were from 12 studies, with 22.8 million individuals followed up for a median of 10 years (IQR 6.4 to 16.9) experiencing 72,792 liver events. Fourteen studies were included in the meta-analysis of obesity (BMI > 30 kg/m2) as a prognostic factor, providing data on 19.3 million individuals followed up for a median of 13.8 years (IQR 9.0 to 19.8) experiencing 49,541 liver events. Obesity was associated with a modest increase in risk of incident severe liver disease outcomes (adjusted HR 1.20, 95% CI 1.12-1.28, p < 0.001, I2 87%). There was also evidence to suggest that lipid abnormalities (low high-density lipoprotein and high triglycerides) and hypertension were both independently associated with incident severe liver disease. Significant study heterogeneity observed in the meta-analyses and possible under-publishing of smaller negative studies are acknowledged to be limitations, as well as the potential effect of competing risks on outcome. CONCLUSIONS: In this review, we observed that T2DM is associated with a greater than 2-fold increase in the risk of developing severe liver disease. As the incidence of diabetes and obesity continue to rise, using these findings to improve case finding for people at high risk of liver disease will allow for effective management to help address the increasing morbidity and mortality from liver disease. TRIAL REGISTRATION: PROSPERO CRD42018115459.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“This leaves information on the association between metabolic risk and NASH/advanced fibrosis coming from cross-sectional and highly selected populations [48].”
BackgroundSelf-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 1×
“Advanced fibrosis is associated with severe liver-related outcomes and increased mortality [3,4].”
BackgroundYounossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationDiabetes increases the risk of chronic liver disease and hepatocellular carcinoma
El-serag, H. B., Tran, T., & Everhart, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.065 · Cited by 1,230
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,060
Self-citationMcPherson, S., Stewart, S. F., Henderson, E., Burt, A. D., & Day, C. P. (2010) · Gut · doi:10.1136/gut.2010.216077 · Cited by 946
A guide to systematic review and meta-analysis of prognostic factor studies
Riley, R. D., Moons, K. G. M., Snell, K. I. E., Ensor, J., Hooft, L., Altman, D. G., Hayden, J., Collins, G. S., & Debray, T. P. A. (2019) · BMJ · doi:10.1136/bmj.k4597 · Cited by 742
Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., Ferguson, J., Forton, D., Foster, G., Gilmore, S. I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61838-9 · Cited by 602
Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.057 · Cited by 502
Srivastava, A., Gailer, R., Tanwar, S., Trembling, P., Parkes, J., Rodger, A., Suri, D., Thorburn, D., Sennett, K., Morgan, S., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.033 · Cited by 446
Nonalcoholic fatty liver disease in patients with type 2 diabetes
Younossi, Z. M., Gramlich, T., Matteoni, C. A., Boparai, N., & McCullough, A. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00014-x · Cited by 443
Sberna, A. L., Bouillet, B., Rouland, A., Brindisi, M. C., Nguyen, A., Mouillot, T., Duvillard, L., Denimal, D., Loffroy, R., Vergès, B., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13565 · Cited by 322
Kanwal, F., Kramer, J. R., Li, L., Dai, J., Natarajan, Y., Yu, X., Asch, S. M., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31014 · Cited by 319
Alexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1321-x · Cited by 317
Stepanova, M., Rafiq, N., & Younossi, Z. M. (2010) · Gut · doi:10.1136/gut.2010.213553 · Cited by 303
Stepanova, M., Rafiq, N., Makhlouf, H., Agrawal, R., Kaur, I., Younoszai, Z., McCullough, A., Goodman, Z., & Younossi, Z. M. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2743-5 · Cited by 301
Koutoukidis, D. A., Astbury, N. M., Tudor, K. E., Morris, E., Henry, J. A., Noreik, M., Jebb, S. A., & Aveyard, P. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2248 · Cited by 270
Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M. (2018) · Medicine · doi:10.1097/md.0000000000010214 · Cited by 221
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s004 · Cited by 207
Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study
Liu, B., Balkwill, A., Reeves, G., Beral, V., & Collaborators., O. B. O. T. M. W. S. (2010) · BMJ · doi:10.1136/bmj.c912 · Cited by 202
Younossi, Z. M., Otgonsuren, M., Venkatesan, C., & Mishra, A. (2013) · Metabolism · doi:10.1016/j.metabol.2012.08.005 · Cited by 169
Williams, R., Alexander, G., Armstrong, I., Baker, A., Bhala, N., Camps-Walsh, G., Cramp, M. E., de Lusignan, S., Day, N., Dhawan, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32866-0 · Cited by 169
Pang, Y., Kartsonaki, C., Turnbull, I., Guo, Y., Clarke, R., Chen, Y., Bragg, F., Yang, L., Bian, Z., Millwood, I. Y., et al. (2018) · Hepatology · doi:10.1002/hep.30083 · Cited by 166
Newly diagnosed diabetes mellitus as a risk factor for serious liver disease
Porepa, L. F., Ray, J. G., Sanchez-Romeu, P., & Booth, G. L. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.092144 · Cited by 142
Ioannou, G. N., Weiss, N. S., Kowdley, K. V., & Dominitz, J. A. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01200-9 · Cited by 129
Harman, D. J., Ryder, S. D., James, M. W., Jelpke, M., Ottey, D., Wilkes, E., Card, T. R., Aithal, G. P., & Guha, I. N. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-007516 · Cited by 117
Hagström, H., Tynelius, P., & Rasmussen, F. E. (2017) · Gut · doi:10.1136/gutjnl-2016-313622 · Cited by 98
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Francque, S., & Vonghia, L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00898-6 · Cited by 92
Hagström, H., Stal, P. I., Hultcrantz, R. W., Hemmingsson, T., & Andréasson, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.019 · Cited by 89
Pelusi, S., Petta, S., Rosso, C., Borroni, V. N., Fracanzani, A. L., Dongiovanni, P., Craxì, A., Bugianesi, E., Fargion, S. R., & Valenti, L. V. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163069 · Cited by 83
Nderitu, P., Bosco, C., Garmo, H., Holmberg, L., Malmström, H., Hammar, N., Walldius, G., Jungner, I., Ross, P. J., & Hemelrijck, M. V. (2017) · International Journal of Cancer · doi:10.1002/ijc.30818 · Cited by 79
Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes
Björkström, K., Franzén, S., Eliasson, B., Miftaraj, M., Guðbjörnsdóttir, S., Lagerros, Y. T., Svensson, A., & Hagström, H. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.038 · Cited by 79
Tanajewski, Ł., Harris, R., Harman, D. J., Aithal, G. P., Card, T. R., Gkountouras, G., Berdunov, V., Guha, I. N., & Elliott, R. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015659 · Cited by 77
Morling, J. R., Fallowfield, J. A., Guha, I. N., Nee, L. D., Glancy, S., Williamson, R. M., Robertson, C. M., Strachan, M. W. J., & Price, J. F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.10.017 · Cited by 73
Otgonsuren, M., Stepanova, M., Gerber, L. H., & Younossi, Z. M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2446-3 · Cited by 64
Andréasson, A., Carlsson, A. C., Önnerhag, K., & Hagström, H. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.02.040 · Cited by 58
Simeone, J. C., Bae, J. P., Hoogwerf, B. J., Li, Q., Haupt, A., Ali, A. K., Boardman, M. K., & Nordstrom, B. L. (2017) · Clinical Epidemiology · doi:10.2147/clep.s144368 · Cited by 57
Hallsworth, K., Avery, L., & Trenell, M. I. (2016) · Current Gastroenterology Reports · doi:10.1007/s11894-016-0485-1 · Cited by 52
Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study
Goh, G. B., Pan, A., Chow, W. C., Yuan, J., & Koh, W. (2016) · Liver International · doi:10.1111/liv.13241 · Cited by 45
El-Gohary, M., Moore, M. V., Roderick, P. J., Watkins, E., Dash, J., Reinson, T., Newell, C., Kim, M., Stuart, B. L., Becque, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208798 · Cited by 43
Ioannou, G. N., Weiss, N. S., Boyko, E. J., Kowdley, K. V., Kahn, S. E., Carithers, R. L., Tsai, E. C., & Dominitz, J. A. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00442-2 · Cited by 40
Waist-to-hip ratio but not body mass index predicts liver cirrhosis in women
Schult, A., Mehlig, K., Björkelund, C., Wallerstedt, S., & Kaczynski, J. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1420219 · Cited by 27
Overweight and hypertriglyceridemia are risk factors for liver cirrhosis in middle-aged Swedish men
Schult, A., Eriksson, H., Wallerstedt, S., & Kaczynski, J. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.560679 · Cited by 20
Hagström, H., Höijer, J., Andréasson, A., Bottai, M., Johansson, K., Ludvigsson, J. F., & Stephansson, O. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15162 · Cited by 7
Cited by
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Current status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
A Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Metadata
- Authors
- Jarvis, H., Craig, D., Barker, R., Spiers, G., Stow, D., Anstee, Q. M., & Hanratty, B.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-04-30
- Volume
- 17
- Issue
- 4
- Pages
- e1003100
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W3021836237
- Cited by
- 429
- References
- 56
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.